AZD0780, a novel, oral PCSK9 inhibitor with properties allowing for broad use, food-intake independency and co-administration with other lipid lowering therapies
31 August 2025 (08:15 - 09:00)
Organised by: 
About the speaker
AstraZeneca, Gothenburg (Sweden)
7 More presentations in this session
Miss J. Jannink (Utrecht, NL)
Doctor M. Sghayyer (Birmingham, US)
Access the full session
The Event
ESC Congress 2025
31 August 2025
08:15 CET
You may be interested in
Congress Session
Congress Presentation
